Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:COGT NASDAQ:GHRS NASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$40.50+0.8%$39.70$12.74▼$40.56$6.22B1.111.70 million shs11.33 million shsCOGTCogent Biosciences$36.31+1.3%$34.40$6.94▼$43.73$6.12B0.342.47 million shs4.05 million shsGHRSGH Research$23.61+6.9%$21.15$11.32▼$25.94$1.52B1.31271,016 shs301,518 shsSRRKScholar Rock$51.27+4.2%$47.59$27.07▼$52.19$5.89B0.691.27 million shs2.23 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals+0.40%+1.06%+1.08%+44.07%+223.25%COGTCogent Biosciences+3.76%+8.05%+9.70%+2.52%+395.71%GHRSGH Research-0.67%+8.44%-0.14%+64.97%+79.45%SRRKScholar Rock+3.93%+7.12%+2.20%+16.29%+44.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$40.50+0.8%$39.70$12.74▼$40.56$6.22B1.111.70 million shs11.33 million shsCOGTCogent Biosciences$36.31+1.3%$34.40$6.94▼$43.73$6.12B0.342.47 million shs4.05 million shsGHRSGH Research$23.61+6.9%$21.15$11.32▼$25.94$1.52B1.31271,016 shs301,518 shsSRRKScholar Rock$51.27+4.2%$47.59$27.07▼$52.19$5.89B0.691.27 million shs2.23 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals+0.40%+1.06%+1.08%+44.07%+223.25%COGTCogent Biosciences+3.76%+8.05%+9.70%+2.52%+395.71%GHRSGH Research-0.67%+8.44%-0.14%+64.97%+79.45%SRRKScholar Rock+3.93%+7.12%+2.20%+16.29%+44.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 2.21Hold$41.332.06% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7320.43% UpsideGHRSGH Research 2.73Moderate Buy$40.3871.01% UpsideSRRKScholar Rock 3.12Buy$56.009.23% UpsideCurrent Analyst Ratings BreakdownLatest GHRS, COGT, CNTA, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026SRRKScholar Rock Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.005/19/2026GHRSGH Research HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $65.005/15/2026GHRSGH Research CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/15/2026GHRSGH Research Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $35.005/15/2026GHRSGH Research Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$42.00 ➝ $39.005/8/2026SRRKScholar Rock BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $55.005/8/2026SRRKScholar Rock HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $65.005/6/2026COGTCogent Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.004/21/2026GHRSGH Research Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SRRKScholar Rock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$15M417.77N/AN/A$3.92 per share10.33COGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/AGHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/ASRRKScholar RockN/AN/AN/AN/A$2.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)GHRSGH Research-$48.26M-$0.92N/AN/AN/AN/A-19.36%-18.73%8/6/2026 (Estimated)SRRKScholar Rock-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%8/5/2026 (Estimated)Latest GHRS, COGT, CNTA, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026GHRSGH Research-$0.27-$0.31-$0.04-$0.31N/AN/A5/7/2026Q1 2026SRRKScholar Rock-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.239.539.53COGTCogent Biosciences0.4115.1415.14GHRSGH ResearchN/A34.1334.13SRRKScholar Rock0.718.648.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%COGTCogent BiosciencesN/AGHRSGH Research56.90%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals4.09%COGTCogent Biosciences6.59%GHRSGH ResearchN/ASRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200154.73 million148.34 millionOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableGHRSGH Research1068.61 millionN/AOptionableSRRKScholar Rock140119.83 million103.89 millionOptionableGHRS, COGT, CNTA, and SRRK HeadlinesRecent News About These CompaniesScholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHDJune 22 at 12:24 AM | finance.yahoo.comCasdin Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRKJune 18, 2026 | marketbeat.comArmistice Capital LLC Takes Position in Scholar Rock Holding Corporation $SRRKJune 18, 2026 | marketbeat.comGranahan Investment Management LLC Raises Stock Position in Scholar Rock Holding Corporation $SRRKJune 17, 2026 | marketbeat.comPolar Capital Holdings Plc Buys 527,929 Shares of Scholar Rock Holding Corporation $SRRKJune 17, 2026 | marketbeat.comWhy Scholar Rock’s Workforce Expansion Is Drawing Attention Across BiotechnologyJune 15, 2026 | kalkinemedia.comKFirst Turn Management LLC Buys Shares of 459,727 Scholar Rock Holding Corporation $SRRKJune 14, 2026 | marketbeat.comScholar Rock Holding Corporation $SRRK is Eventide Asset Management LLC's 9th Largest PositionJune 14, 2026 | marketbeat.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 12, 2026 | businesswire.comScholar Rock Holding Corporation $SRRK Shares Sold by Clearbridge Investments LLCJune 11, 2026 | marketbeat.comScholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comScholar Rock Holding Corporation $SRRK Stake Lessened by TD Asset Management IncJune 9, 2026 | marketbeat.comGeode Capital Management LLC Has $89.62 Million Stake in Scholar Rock Holding Corporation $SRRKJune 8, 2026 | marketbeat.comNorges Bank Takes Position in Scholar Rock Holding Corporation $SRRKJune 6, 2026 | marketbeat.comBNP Paribas Financial Markets Has $24.43 Million Position in Scholar Rock Holding Corporation $SRRKJune 6, 2026 | marketbeat.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of "Buy" from BrokeragesJune 6, 2026 | marketbeat.comScholar Rock (NASDAQ:SRRK) Sets New 1-Year High - Here's WhyMay 26, 2026 | marketbeat.comScholar Rock Holding Corp.May 26, 2026 | edition.cnn.comScholar Rock to Present at the 2026 Jefferies Global Healthcare ConferenceMay 20, 2026 | finance.yahoo.comScholar Rock to Present at the 2026 Jefferies Global Healthcare ConferenceMay 20, 2026 | businesswire.comThree Biotechs That Are Top Takeover TargetsMay 18, 2026 | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGHRS, COGT, CNTA, and SRRK Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$40.50 +0.32 (+0.80%) Closing price 04:00 PM EasternExtended Trading$40.71 +0.21 (+0.52%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Cogent Biosciences NASDAQ:COGT$36.31 +0.47 (+1.31%) Closing price 04:00 PM EasternExtended Trading$36.30 -0.01 (-0.01%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.GH Research NASDAQ:GHRS$23.61 +1.52 (+6.88%) Closing price 04:00 PM EasternExtended Trading$23.14 -0.47 (-1.99%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Scholar Rock NASDAQ:SRRK$51.27 +2.08 (+4.23%) Closing price 04:00 PM EasternExtended Trading$50.62 -0.66 (-1.28%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
